Press release
Metastatic Castration-Resistant Prostate Cancer Market is Projected to Witness Significant Growth by 2036 Owing to the Launch of Novel Radioligand Therapies and Targeted Treatments | DelveInsight
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Insights, Epidemiology, and Market Forecast 2036." This comprehensive report provides an in-depth understanding of Metastatic Castration-Resistant Prostate Cancer, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Market
*
The market size for Metastatic Castration-Resistant Prostate Cancer in the leading markets is expected to grow significantly by 2036.
*
DelveInsight estimates that the total mCRPC market in the 7MM was valued at approximately USD 8 billion in 2025.
*
In 2025, the 7MM accounted for approximately 7.7 million prevalent cases of prostate cancer, which are expected to increase during the forecast period.
*
Around 43% of all metastatic prostate cancer cases are attributed to mCRPC.
*
The United States accounted for the highest mCRPC market size in the 7MM in 2025 compared with EU4, the United Kingdom, and Japan.
*
Prostate cancer is the third most prevalent cancer in the United States and the fourth most common cancer worldwide.
*
The number of prostate cancer cases in Japan has increased by nearly 1.8 times over the last decade.
*
Leading mCRPC companies, such as Merck and Orion, Pfizer, Curium, Exelixis, Tavanta Therapeutics, AstraZeneca, Telix International, Lantheus, Eli Lilly/POINT Biopharma, MacroGenics, Promontory Therapeutics, and others, are developing innovative therapies that are expected to enter the market during the forecast period.
*
The promising mCRPC therapies in clinical development include Opevesostat, Mevrometostat, CABOMETYX, 177Lu-PSMA-I&T, 177Lu-PNT2002, TAVT-45, ARV-766, FPI-2265, PT-112, KPG-121, and others.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]
Key Factors Driving the Metastatic Castration-Resistant Prostate Cancer Market
Increasing Prevalence of Prostate Cancer and Aging Population: Increasing life expectancy and the growing burden of prostate cancer are resulting in a larger pool of patients progressing to advanced and castration-resistant disease stages, thereby driving demand for innovative therapies.
Growing Adoption of Precision Medicine and Biomarker-Based Therapies: Advances in molecular diagnostics and genomic profiling are enabling more personalized treatment approaches, accelerating the use of PARP inhibitors, targeted therapies, and biomarker-driven treatment strategies.
Rising Utilization of Radioligand Therapies: The approval and commercial success of PLUVICTO have highlighted the potential of radioligand therapies, encouraging the development of next-generation PSMA-targeted radiopharmaceuticals that are expected to reshape the treatment landscape.
Strong Emerging Pipeline Activity: The mCRPC pipeline remains highly active with novel mechanisms including CYP11A1 inhibitors, EZH2 inhibitors, PROTAC degraders, antibody-drug conjugates, radiopharmaceuticals, and CRBN E3 ligase modulators advancing through clinical development.
Metastatic Castration-Resistant Prostate Cancer Competitive Landscape
Current treatment options for mCRPC include androgen receptor inhibitors, PARP inhibitors, chemotherapy, radiopharmaceuticals, immunotherapies, and supportive therapies. Key marketed products include XTANDI, LYNPARZA, AKEEGA, TALZENNA, PLUVICTO, XOFIGO, and JEVTANA.
Several mCRPC drugs in development include Opevesostat (Merck and Orion), Mevrometostat (Pfizer), CABOMETYX (Exelixis), 177Lu-PSMA-I&T (Curium), 177Lu-PNT2002 (Lantheus/Eli Lilly-POINT Biopharma), TAVT-45 (Tavanta Therapeutics), ARV-766 (Arvinas/Novartis), FPI-2265 (AstraZeneca), PT-112 (Promontory Therapeutics), and KPG-121.
These candidates target diverse mechanisms including CYP11A1 inhibition, EZH2 inhibition, androgen receptor degradation, PSMA-targeted radiotherapy, CRBN E3 ligase modulation, and immune-mediated anti-tumor activity, aiming to improve outcomes and overcome treatment resistance in advanced prostate cancer.
Discover more about therapies set to grab major Metastatic Castration-Resistant Prostate Cancer market share @ Metastatic Castration-Resistant Prostate Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]
Recent Developments in the Metastatic Castration-Resistant Prostate Cancer Market
*
In August 2025, K36 Therapeutics announced that the US FDA cleared the Investigational New Drug (IND) application for KTX-2001 in patients with mCRPC.
*
In June 2025, Pfizer announced FDA approval of updated labeling for TALZENNA in combination with XTANDI, including final overall survival data for HRR gene-mutated mCRPC patients.
*
In April 2025, AstraZeneca discontinued the CAPItello-280 Phase III study evaluating TRUQAP in mCRPC after determining the study was unlikely to meet its primary endpoints.
*
In March 2025, Novartis announced FDA approval of PLUVICTO for patients with PSMA-positive mCRPC who have received androgen receptor pathway inhibitor therapy.
*
In November 2024, Curium announced that its Phase III ECLIPSE trial evaluating 177Lu-PSMA-I&T met its primary endpoint in patients with mCRPC.
What is Metastatic Castration-Resistant Prostate Cancer?
Metastatic Castration-Resistant Prostate Cancer (mCRPC) is an advanced form of prostate cancer that continues to progress despite androgen deprivation therapy and castrate levels of testosterone. Patients experience disease progression through rising prostate-specific antigen levels, radiographic progression, or worsening clinical symptoms. Although multiple treatment options are available, mCRPC remains a challenging and life-threatening condition requiring continuous therapeutic innovation.
Metastatic Castration-Resistant Prostate Cancer Epidemiology Segmentation
The Metastatic Castration-Resistant Prostate Cancer epidemiology section provides insights into the historical and current patient pool and forecasted trends for the leading markets. The mCRPC market report provides epidemiological analysis for the study period 2022-2036 segmented into:
*
Total Prevalent Cases of Prostate Cancer
*
Five-year Prevalent Cases of Prostate Cancer
*
Age-specific Cases of Prostate Cancer
*
Clinical Stage-specific Cases of Prostate Cancer
*
Metastatic Cases of Prostate Cancer
*
Total Prevalent Cases of mCRPC
*
Drug-treated Cases of mCRPC
Scope of the Metastatic Castration-Resistant Prostate Cancer Market Report
*
Therapeutic Assessment: Metastatic Castration-Resistant Prostate Cancer current marketed and emerging therapies
*
Market Dynamics: Key Market Forecast Assumptions of Emerging mCRPC Drugs and Market Outlook
*
Key Companies: Merck and Orion, Pfizer, Curium, Exelixis, Tavanta Therapeutics, AstraZeneca, Telix International, Lantheus, Eli Lilly/POINT Biopharma, MacroGenics, Promontory Therapeutics, and others
*
Key Therapies: Opevesostat, Mevrometostat, CABOMETYX, 177Lu-PSMA-I&T, 177Lu-PNT2002, TAVT-45, ARV-766, FPI-2265, PT-112, XTANDI, LYNPARZA, AKEEGA, TALZENNA, PLUVICTO, and others
*
Competitive Intelligence Analysis: SWOT analysis and Market Entry Strategies
*
Unmet Needs, KOL's Views, Analyst's Views, Market Access and Reimbursement
To know more about Metastatic Castration-Resistant Prostate Cancer companies working in the treatment market, visit @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]
Table of Contents
*
Metastatic Castration-Resistant Prostate Cancer Market Report Introduction
*
Executive Summary for Metastatic Castration-Resistant Prostate Cancer
*
SWOT Analysis of Metastatic Castration-Resistant Prostate Cancer
*
Metastatic Castration-Resistant Prostate Cancer Patient Share (%) Overview at a Glance
*
Metastatic Castration-Resistant Prostate Cancer Market Overview at a Glance
*
Metastatic Castration-Resistant Prostate Cancer Background and Overview
*
Metastatic Castration-Resistant Prostate Cancer Epidemiology and Patient Population
*
Country-Specific Patient Population of Metastatic Castration-Resistant Prostate Cancer
*
Metastatic Castration-Resistant Prostate Cancer Current Treatment and Medical Practices
*
Metastatic Castration-Resistant Prostate Cancer Unmet Needs
*
Metastatic Castration-Resistant Prostate Cancer Emerging Therapies
*
Metastatic Castration-Resistant Prostate Cancer Market Outlook
*
Country-Wise Metastatic Castration-Resistant Prostate Cancer Market Analysis (2022-2036)
*
Metastatic Castration-Resistant Prostate Cancer Market Access and Reimbursement of Therapies
*
Metastatic Castration-Resistant Prostate Cancer Market Drivers
*
Metastatic Castration-Resistant Prostate Cancer Market Barriers
*
Metastatic Castration-Resistant Prostate Cancer Appendix
*
Metastatic Castration-Resistant Prostate Cancer Report Methodology
*
DelveInsight Capabilities
*
Disclaimer
*
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-castrationresistant-prostate-cancer-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-launch-of-novel-radioligand-therapies-and-targeted-treatments-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Castration-Resistant Prostate Cancer Market is Projected to Witness Significant Growth by 2036 Owing to the Launch of Novel Radioligand Therapies and Targeted Treatments | DelveInsight here
News-ID: 4560140 • Views: …
More Releases from ABNewswire
Children's Mercy Partners with Heartland Soccer for 2026 Heartland Invitational …
New partnership supports two weekends of youth soccer competitions in the Kansas City metro
Overland Park, Kansas - October 27, 2026 - Heartland Soccer Association is proud to announce Children's Mercy as the title sponsor of the 2026 Children's Mercy Heartland Invitational Tournaments, launching a new partnership focused on supporting young athletes, families and youth sports throughout the Kansas City community.
The annual Heartland Invitational Tournaments will bring thousands of players, coaches…
Zhonglian Chemical Strengthens B2B Sourcing Support for Food Grade Silica and Sp …
Shandong Zhonglian Chemical Co., Ltd. supplies food grade silica, silicon dioxide E551, anti-caking silica, adsorbent silica, toothpaste grade silica, and specialty silica products. As Zhongqi's authorized overseas sales subsidiary, Zhonglian supports global B2B buyers with product information and application guidance to help identify suitable silica grades for their manufacturing needs.
Jinan, Shandong, China - October 27, 2026 - Shandong Zhonglian Chemical Co., Ltd. [https://www.silicaplant.com/], operating under the Zhonglian brand, continues to…
The Same Week Can Go Two Ways: Nonprofit Behind MakeChoice Asks Public to Help K …
Changing Our Futures, a California 501(c)(3) nonprofit, has launched a year-end campaign to keep MakeChoice.org free for the more than 15,000 people who use it each month. These are people facing loneliness, family conflict, job loss and other hard moments. Contributions will also support food, shelter and youth programs and help build the MakeChoice Village, a planned park where people can find help before a hard week becomes a crisis.
California,…
Kunbao Expands Custom Gel Sheet and Gel Pad Manufacturing Solutions for Global O …
Jiangmen Kunbao New Materials Co., Ltd. (Kunbao/KBCoolGel) is a gel material manufacturer with experience dating back to 2011. The company specializes in PU gel, hydrogel, custom gel sheets, gel pads, gel seat cushions, medical positioning gel pads, and cooling gel mattress components. With 400+ existing molds, Kunbao provides custom molding, gel-foam integration, OEM and ODM services, and tailored solutions for global manufacturers and brands.
Jiangmen, Guangdong, China - October 27, 2026…
More Releases for Prostate
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre …
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions.
The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causes…
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat …
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues.
The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg
At the heart of this…
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm …
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution.
The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Men…
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods.
As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care.
This innovative therapy…
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro …
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues.
At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitment…
The 3D Urology and Prostate Clinics Introduce Groundbreaking Non-Surgical Prosta …
The 3D Urology and Prostate Clinics introduced a holistic approach to treating prostate and genitourinary conditions with their 3D Natural Prostate Treatment.
The frequency with which patients come to the 3D Urology and Prostate Clinics is a testament to the success of their prostate and genitourinary treatments. These clinics specialize in treating chronic prostatitis, enlarged prostate, and other prostate-related conditions using 3D natural prostate treatment. This non-surgical, non-invasive approach has proven…
